LaChapelle Robin 4

What Happened

• Robin LaChapelle, Chief Operating Officer of ArriVent BioPharma, was granted a derivative award covering 130,000 shares on February 2, 2026. The reporting shows a $0.00 price (no cash paid at grant) and the award is reported as a derivative instrument (an option covering shares).

Key Details

• Transaction date: 2026-02-02; Filing date: 2026-02-04.
• Reported price: $0.00; Type: Award/Grant of a derivative (option) covering 130,000 shares.
• Vesting: 25% vests on February 2, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing details.
• Timeliness: Filing was submitted two days after the transaction; no late-filing indication in the record provided.

Context

• This was a compensation-related option grant, not an open-market purchase or sale. Such awards are common for executives and vest over time contingent on continued employment, so they reflect incentive alignment rather than an immediate market bet.